Antioxidant supplementation, particularly with coenzyme Q10 (CoQ10), has gained prominence as a therapeutic strategy to enhance fertility outcomes and ART success
With respect to GLP-1RAs, liraglutide and semaglutide have demonstrated a reduction in the risk of major adverse cardiovascular events (MACE) [16, 17], and, while yet not published, early reports for dulaglutide indicate CV benefits in patients with a wide range of CV risk [18]
As demand for obesity management, glucose control, and chronic care solutions accelerates worldwide, these brands continue to dominate physician trust, patient adoption, and market growth
Transitioning to SCIG reduces the risk and severity of common and more serious side effects
It is best to follow the label exactly unless a healthcare professional recommends another plan